Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors.
Johanna WinterMax M LendersMaximilian GassenmaierAndrea ForschnerUlrike LeiterBenjamin WeideMette-Triin PurdeLukas FlatzAntonio CozzioMartin RöckenClaus GarbeThomas K EigentlerNikolaus Benjamin WagnerPublished in: Cancer immunology, immunotherapy : CII (2020)
The frequency of hepatic irAE is currently underestimated. The addition of the sensitive enzyme GGT to the laboratory panel before and during therapy with ICPI allows to detect two to three times more patients developing hepatic or hepatobiliary toxicity than known so far. Immune-related GGT elevations correlate with response and favorable survival. Precis for use in the Table of Contents The frequency of hepatotoxicity under immune checkpoint blockade is currently underestimated. We suggest the addition of gamma-glutamyl transferase to the laboratory panel in checkpoint inhibitor patients for the detection of hepatobiliary toxicity.